Novo Nordisk's 1st-qtr 2024 sales increased 22%
Danish diabetes giant Novo Nordisk (NOV: N) today reported financial results for the first quarter of 2024, noting that sales increased by 22% in Danish kroner and by 24% at constant exchange rates to 65.3 billion kroner ($9.35 billion), almost 2 billion-kroner higher than forecast by analysts surveyed by Bloomberg and financial data firm FactSet.
Operating profit increased by 27% in kroner and by 30% at constant exchange rates (CER) to 31.8 billion kroner. Notwithstanding the positive results, Novo Nordisk’s shares dipped 2.4% to 876.00 kroner by mid-morning.
Sales in North America Operations increased by 34% in kroner (35% at CER). Sales growth in the USA was positively impacted by gross-to-net sales adjustments related to prior years. Sales in International Operations increased by 8% in kroner (11% at CER).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze